Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: iStock
Takeda Biopharmaceuticals India today announced that QDENGA (TAK-003) has become the first dengue vaccine to receive approval in India, marking a major milestone in the country's fight against the mosquito-borne disease.
The Drug Controller General of India (DCGI) has granted market authorization for QDENGA to prevent dengue in individuals aged 4-60 years. According to Takeda, it is India's first approved dengue vaccine and can be administered regardless of previous dengue infection, without requiring pre-vaccination testing.
"Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India," said Dr. Mahender Nayak, Head of Intercontinental Markets.
The approval comes at a critical time as dengue cases in India have risen sharply over the past two decades.
India accounts for nearly one-third of the global dengue burden. In 2025, more than 113,000 dengue cases were officially reported, although modelling studies suggest the true number of infections may run into tens of millions annually due to underreporting.
Rapid urbanization, climate change and widespread mosquito breeding have made dengue a year-round public health concern. Since there is no specific antiviral treatment for dengue, prevention remains the most effective strategy.
"India carries a substantial dengue burden, and all four dengue virus serotypes co-circulate in several regions. QDENGA is designed to protect against all four serotypes regardless of prior exposure," said Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster.
The DCGI approval is supported by Takeda's global clinical development programme comprising 19 Phase 1, 2 and 3 clinical trials involving more than 28,000 participants in dengue-endemic and non-endemic regions.
The pivotal Phase III TIDES (DEN-301) study enrolled more than 20,000 participants across eight countries and evaluated the vaccine's long-term safety and effectiveness.
Key findings include:
The approval is also supported by an Indian Phase III (DEN-302) trial involving participants aged 4-60 years, which found QDENGA to be safe, well-tolerated and immunogenic in children, adolescents and adults.
QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.
It is administered as two 0.5 mL subcutaneous doses, given three months apart.
The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection.
The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO.
The vaccine has been approved in 43 countries across Asia, Latin America and Europe. It is already part of Brazil's National Immunization Program and is available through public immunization programmes in Argentina, Colombia and Indonesia.
The vaccine is approved in India for people aged 4-60 years to help prevent dengue disease.
Takeda had partnered with Indian vaccine manufacturer Biological E in 2024 to expand production of QDENGA.
Under the agreement, Biological E plans to manufacture 50 million doses annually, supporting Takeda's goal of producing 100 million doses globally each year by the end of the decade.
Credit: iStock
COVID-19 is seeing a renewed uptick in India, with 339 infections reported between July 1 and July 16, according to the Andhra Pradesh Health Department.
Andhra Pradesh has reported four COVID-related deaths and 19 active cases, prompting heightened surveillance after officials identified the Omicron RF.5 sublineage in infected patients in the state.
The presence of RF.5 sublineage in Andhra was confirmed through genome sequencing of patient samples from YSR Kadapa district at the National Institute of Virology (NIV), Pune.
According to the Andhra Pradesh Health Department states that reported COVID infections fromJuly 1-16 include:
RF.5 is an Omicron sublineage identified through genome sequencing. The World Health Organization (WHO) is monitoring the variant after it was reported in higher numbers in Singapore and other parts of Southeast Asia, prompting Indian health authorities to closely track its spread.
According to the Andhra Pradesh government, RF.5 evolved naturally from the Omicron JN.1 lineage through the LF.7 and PY.1.1.1 sublineages.
Officials said it is not a recombinant variant, meaning it evolved within a single genetic lineage rather than through the combination of two different variants.
Based on current evidence, Dr. Vishnuvardhan said there is no indication that RF.5 causes more severe disease than other Omicron subvariants currently in circulation, although continued surveillance remains important.
The symptoms of RF.5 are similar to those seen with other Omicron variants and include:
In a post on X, Dr. Vipin M. Vashishtha, Member of the WHO Vaccine Safety Net (VSN), said RF.5 carries several spike mutations that may influence how the virus behaves:
However, Dr. Vashishtha said these mutations alone should not be considered reliable predictors of disease severity. RF.5 continues to be monitored through WHO genomic surveillance.
According to health officials, there is currently no cause for alarm.
Health officials advise people to:
Credit: iStock
Amid the ongoing Cyclospora parasite outbreak linked to lettuce supplied by Taylor Farms, the produce company has recalled shredded iceberg lettuce distributed across 27 US states over possible contamination concerns.
The outbreak, which has been under investigation for more than a month, has sickened over 5,000 people across at least 34 states, causing widespread cases of diarrhea.
The Centers for Disease Control and Prevention (CDC) initially linked the outbreak to lettuce supplied by Taylor Farms to Taco Bell restaurants in five states earlier this week. However, a recall notice issued by the company late last week indicated that the potentially contaminated lettuce had a much wider distribution.
Taylor Farms said it is "actively removing" the affected products, has suspended distribution of iceberg lettuce imported from Central Mexico to the United States, and is no longer receiving products from the implicated lot.
"Consumers who have purchased the recalled iceberg lettuce should discard it immediately and not consume it," the company said.
Also read: Cyclospora Parasite Outbreak: Why You Should Avoid Packaged Salads and Go For Loose Greens
According to Taylor Farms, the recalled shredded iceberg lettuce was distributed between June 29 and July 16 in:
Alabama, Arkansas, Connecticut, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia and Wisconsin.
The recall notice includes product descriptions, brand abbreviations and use-by dates but does not identify specific retailers, restaurants or product names.
"At this time, Taylor Fresh Foods has not publicly provided distribution information or a list of customers who received the product that was voluntarily removed from the market," the US Food and Drug Administration (FDA) said.
The FDA also noted that an earlier lettuce sample from Taylor Farms initially tested positive for Cyclospora but later determined the result "should be considered a false positive."
"FDA and state partners continue to collect and analyze product samples," the agency said, adding that no confirmed positive samples have been identified so far.
Taylor Farms also said on social media that none of its Taylor Farms-branded salad kits are associated with the outbreak. Most of the recalled lettuce was sold in large bags to food-service operations, including restaurants, with many products blended with romaine lettuce.
Further, media reports stated that several companies have begun removing affected products from stores and supply chains.
The list includes
Food safety experts said that additional distributors and restaurants may also have received the recalled lettuce, even if they have not publicly disclosed it.
The FDA said Taylor Farms "has not publicly provided distribution information or a list of customers who received the product that was voluntarily removed from the market." Current FDA regulations do not require companies to disclose that information.
Sandra B. Eskin, chief executive of Stop Foodborne Illness, said the lack of transparency can limit the effectiveness of recalls. She added, "The whole point is to quickly identify the product and make sure no one else eats it."
Health officials recommend:
Experts also recommend choosing whole heads of lettuce instead of bagged greens. Remove the outer leaves, wash the inner leaves thoroughly under running water, and cook produce whenever possible, as heat is the most effective way to kill Cyclospora.
© 2024 Bennett, Coleman & Company Limited